A new player is on the verge of entering the astaxanthin and other markets with the granting of a patent on a ‘dark fermentation’ process for cultivating Haematococcus pluvialis and other algae species.
Zivo Bioscience, an algae company long focused on deriving unique bioactives from its proprietary strains, has pivoted to protein as developers realized the potential inherent in the straight, unrefined biomass.
EF Hutton, a one-time stock brokerage, used to bill itself as “the quiet company.” Arizona-based Heliae could be said to have filled that role in the algal ingredients space, though that stance may be changing.